Galdu-irabazien kontua
XENON PHARMACEUTICALS INC.
XENE
Errendimenduaren laburpena
Egin klik taulako edozein lerrotan grafikoan gehitzeko
milioika USDtan
| Neurria | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Diru-sarrerak
|
- | - | - | - | - | - | - | - | 0.31 | 1.80 | 15.58 | 28.37 |
|
Diru-sarreren kostua
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Irabazi gordina
|
- | - | - | - | - | - | - | - | 0.31 | 1.80 | 15.58 | 28.37 |
|
Ustiapen-gastuak
|
380.57 | 279.30 | 214.05 | 138.58 | 97.43 | 63.47 | 49.65 | 38.02 | 32.89 | 26.62 | 24.94 | 17.26 |
|
Ikerketa eta garapena
|
300.94 | 210.39 | 167.51 | 105.77 | 75.46 | 50.52 | 38.85 | 23.63 | 25.57 | 19.83 | 15.15 | 11.77 |
|
Salmentak, orokorrak eta administratiboak
|
79.63 | 68.90 | 46.54 | 32.81 | 21.97 | 12.94 | 10.80 | 8.38 | 7.31 | 6.79 | 9.79 | 5.50 |
|
Beste ustiapen-gastu batzuk
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Ustiapen-irabaziak
|
-380.57 | -279.30 | -214.05 | -138.58 | -97.43 | -63.47 | -49.65 | -38.02 | -32.58 | -24.82 | -9.36 | 11.11 |
|
Ez-ustiapeneko diru-sarrerak
|
28.18 | 40.88 | 31.37 | 3.89 | -18.54 | -34.37 | -8.03 | - | - | - | - | - |
|
Interesen diru-sarrerak
|
26.83 | 41.94 | 27.62 | 8.71 | 0.47 | 2.28 | 2.35 | 1.22 | 0.48 | 0.50 | 0.54 | 0.57 |
|
Interesen gastuak
|
- | - | - | - | - | 0.48 | 1.43 | 1.39 | 0.02 | - | - | - |
|
Beste ez-ustiapeneko diru-sarrerak/gastuak
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Zerga aurreko irabazia
|
-344.89 | -238.42 | -182.69 | -125.26 | -78.89 | -29.09 | -41.62 | - | - | - | - | - |
|
Zerga-gastua
|
1.02 | -4.09 | -0.29 | 0.12 | -0.01 | -0.26 | -0.02 | - | - | - | - | - |
|
Partaidetza ez-kontrolatzailea
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Irabazi garbia
|
-345.91 | -234.33 | -182.39 | -125.37 | -78.88 | -28.84 | -41.60 | -34.50 | -30.70 | -23.00 | -15.75 | 13.02 |
Informazio osagarria
Akzioko datuak, eratorritakoak eta bestelakoak — ez dira galdu-irabazien kontuaren parte
milioika USDtan, bestela adierazi ezean
| Neurria | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Amortizazioa eta balio-galera
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
-378.03 | -276.74 | -210.51 | -136.95 | -96.52 | -62.82 | -49.22 | -37.43 | -31.93 | -23.95 | -8.32 | 11.84 |
|
Akzioko irabazia (oinarrizkoa)
|
-4.36 | -3.01 | -2.73 | -2.06 | - | - | - | -1.63 | -1.71 | -1.48 | -1.10 | 4.11 |
|
EPS diluitua
|
-4.36 | -3.01 | -2.73 | -2.06 | - | - | - | -1.63 | -1.72 | -1.48 | -1.10 | 3.28 |
|
Akzioen batez besteko haztatua
|
79.25 | 77.89 | 66.89 | 60.54 | - | - | - | 19.43 | 17.99 | 15.49 | 14.28 | 3.17 |
|
Akzioen batez besteko haztatu diluitua
|
79.25 | 77.89 | 66.89 | 60.54 | - | - | - | 19.43 | 18.00 | 15.49 | 14.28 | 3.96 |
|
Irabazi globala
|
-343.96 | -235.87 | -179.47 | -127.38 | - | - | - | - | - | -23.00 | -15.75 | 9.52 |